TITLE

Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments

AUTHOR(S)
Inderjeeth, Charles; Chan, Kien; Kwan, Kevin; Lai, Michelle
PUB. DATE
September 2012
SOURCE
Journal of Bone & Mineral Metabolism;Sep2012, Vol. 30 Issue 5, p493
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Early prevention of future fracture is an important goal in those at risk. A similar 3-year fracture efficacy is reported for most osteoporosis agents. Onset of fracture efficacy may be useful to help tailor treatment based on risk. We reviewed the peer-reviewed literature for onset of fracture efficacy data on the commonly prescribed osteoporosis treatments. All papers were reviewed independently by at least two reviewers for onset of efficacy for morphometric vertebral fracture (MVF), clinical vertebral fracture (CVF), nonvertebral fracture (NVF), hip fracture, and any clinical fracture (ACF). Alendronate is reported to reduce multiple CVF by 6 months; all CVF, NVF, and multiple ACF by 12 months; and all ACF and hip fracture by 18 months. Ibandronate is reported to reduce MVF by 12 months and NVF by 36 months. Raloxifene is reported to reduce CVF by 3-6 months and NVF by 36 months. Risedronate is reported to reduce CVF and NVF by 6 months, and hip fracture by 12 months. Strontium ranelate is reported to reduce MVF, CVF, NVF, and ACF by 12 months, and hip fracture by 36 months. Zoledronic acid is reported to reduce MVF, CVF, and ACF by 12 months, NVF by 24 months, and hip fracture by 36 months. Although direct comparisons are limited, based on the available literature, risedronate, followed by alendronate, have the earliest onset of benefit across the range of fracture types. Onset of efficacy may be an important consideration in the selection of treatment for some patients.
ACCESSION #
79824420

 

Related Articles

  • OSTEOPOROSIS TREATMENTS.  // Monthly Prescribing Reference;Oct2014, Vol. 30 Issue 10, p173 

    A chart is presented on several drugs for the treatment of osteoporosis, that includes information on the drugs alendronate, risedronate, and zoledronic acid.

  • Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. Wong, Peter; Borromeo, Gelsomina; Wark, John // Rheumatology International;Sep2013, Vol. 33 Issue 9, p2189 

    Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget's disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may...

  • OSTEOPOROSIS TREATMENTS.  // Monthly Prescribing Reference;May2015, Vol. 31 Issue 5, p177 

    The article offers information on several drugs used to treat osteoporosis. Among the drugs are Alendronate, Risedronate, and Zoledronic acid. The risk factors of osteoporosis and the recommended amount of calcium and vitamin D that should be taken by patients per day were indicated. Also...

  • Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates. Sprini, Delia; Di Stefano, Laura; Battista Rini, Giovam; Cianferotti, Luisella; Napoli, Nicola // Clinical Cases in Mineral & Bone Metabolism;2014, Vol. 11 Issue 2, p126 

    Treatment with bisphosphonates induces differentiation and activation of Vγ9Vδ2 T lymphocytes obtained from peripheral blood showing also an anti-tumoral effect in both in vitro and in vivo models. Aim of the present study was to determine in vivo the effect of BPs treatment in patients...

  • Alendronic acid/zoledronic acid.  // Reactions Weekly;1/25/2014, Issue 1485, p6 

    The article presents case studies of a 64-year-old woman and a 62-year-old woman who experienced osteonecrosis of the jaw (ONJ) following the administration of zoledronic acid and alendronic acid, respectively, after a root canal treament.

  • Alendronic acid/ibandronic acid/zoledronic acid.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p22 

    The article presents case study of four women who developed atypical fractures while having prolonged treatment with alendronic acid, ibandronic acid and/or zoledronic acid. It reflects on a 74-year-old woman having history of Colles fracture and vitamin D insufficiency. It mentions a...

  • Zoledronic Acid Treatment of Osteoporosis in Men. Kurmky, Louis // Infectious Disease Alert;Jan2013 Clinical Briefs in Primary Care, p2 

    The article provides information on a study published in a 2012 issue of the "New England Journal of Medicine," which evaluated the effectiveness of the drug zoledronic acid in the treatment of osteoporosis in men.

  • Alendronic acid/risedronic acid/zoledronic acid.  // Reactions Weekly;May2014, Vol. 1499 Issue 1, p6 

    An abstract of the article "Atypical fractures of the femur related to prolonged treatment with Bisphosphonates for osteoporosis," by Y. Rosenthal and colleagues is presented.

  • Uveítis por ácido zolendrónico: reporte de un caso y revision de la bibliografía. Albani-Campanario, Mario; Buendía-Díaz, Gerardo; De Lourdes Flores-Islas, María; Maquita-Nakano, Carlos; Ochoa-Cervantes, Josefina // Ginecologia y Obstetricia de Mexico;May2012, Vol. 80 Issue 5, p355 

    There are several treatment options for postmenopausic patients suffering from ostopenia or osteoporosis; one of them being inhibition of bone resorption using bisphosphonates. The most common side effects of these drugs are of gastrointestinal nature. There are, of course, other side effects...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics